High-flow Nasal Oxygenation in Obese Patients During Colonoscopy: a Randomized Controlled Trial (COCOON) (COCOON)
High-flow Nasal Oxygenation in Obese Patient During Colonoscopy: a Randomized Controlled Trial: the COCOON Trial
The goal of this clinical trial is to determine whether high-flow oxygen therapy (HFOT) is more effective than conventional oxygen therapy (COT) in reducing episodes of intraoperative oxygen desaturation (oxygen saturation [SpO2] ≤ 90%) during colonoscopy under general anesthesia in adults with a body mass index (BMI) of 30 kg/m² or higher.
The main question it aims to answer is:
Does high-flow oxygen therapy reduce the occurrence of intraoperative oxygen desaturation compared with conventional oxygen therapy during colonoscopy under general anesthesia? Researchers will compare high-flow oxygen therapy with conventional oxygen therapy to determine whether high-flow oxygen therapy reduces the occurrence of intraoperative oxygen desaturation.
Participants will:
Be screened during their anesthesia consultation between 60 days and 48 hours before the scheduled colonoscopy.
Be randomly assigned (1:1) to receive either conventional oxygen therapy or high-flow oxygen therapy. Receive standard monitoring and 3 minutes of pre-oxygenation according to their assigned treatment group.
Undergo colonoscopy under general anesthesia while breathing spontaneously. Be monitored for oxygen desaturation during the procedure. Have ventilatory and hemodynamic data recorded during the procedure and collected immediately after the colonoscopy.
The study will include adults scheduled for a colonoscopy at Bichat-Claude Bernard Hospital, Beaujon Hospital, or Louis Mourier Hospital.
Przegląd badań
Status
Status
Warunki
Warunki
Interwencja / Leczenie
Interwencja / Leczenie
Szczegółowy opis
Prospective, multicentre, controlled, randomized, parallel-group superiority trial with a 1:1 allocation ratio, with participants blinded to the oxygen treatment received, comparing high-flow oxygen therapy (HFOT) with conventional oxygen therapy (COT) delivered through an oxygen mask. The study aims to determine whether HFOT is more effective than COT in preventing intraoperative oxygen desaturation during colonoscopy under general anesthesia in participants with a body mass index (BMI) of 30 kg/m² or higher.
Adults with a body mass index (BMI) of 30 kg/m² or higher who are scheduled to undergo a colonoscopy at Bichat-Claude Bernard Hospital, Beaujon Hospital, or Louis Mourier Hospital.
After written informed consent has been obtained, participants will be randomized by the study investigators to one of the two treatment groups: conventional oxygen therapy (COT); high-flow oxygen therapy (HFOT).
A computer-generated randomization list with a 1:1 allocation ratio and variable block sizes will be prepared by a statistician from the URC Paris Nord Secteur Ouest, in accordance with the sponsor's procedures. Allocation will be concealed, as the randomization list will not be accessible to the study team. The list will be directly integrated into CleanWEB™, a secure, centralized, 24- hour Internet platform, which will also be used for the electronic case report form (eCRF).
Typ studiów
Typ studiów
Zapisy (Szacowany)
Zapisy
Faza
Faza
- Nie dotyczy
Kontakty i lokalizacje
Kontakt w sprawie studiów
Kontakt w sprawie studiów
- Nazwa: Jules STERN
- Numer telefonu: +33140258080
- E-mail: jules.stern@aphp.fr
Kopia zapasowa kontaktu do badania
- Nazwa: Ines CHIBANE, +33140257961
- E-mail: ines.chibane@aphp.fr
Lokalizacje studiów
-
-
-
Clichy, Francja, 92110
- Hôpital Beaujon, département d'anesthésie-réanimation, 100 boulevard du Général Leclerc
-
Kontakt:
- Stéphanie SIGAUT, Principal Investigator
-
Colombes, Francja, 92700
- Hôpital Louis Mourier, département d'anesthésie-réanimation, 178 rue des Renouillers
-
Paris, Francja, 75018
- Hôpital Bichat-Claude Bernard, département d'anesthésie-réanimation, 46 rue Henri Huchard
-
Kontakt:
- Jules STERN, Principal Investigator
- Numer telefonu: +33140258080
- E-mail: jules.stern@aphp.fr
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Age 18 years or older.
- Body mass index (BMI) of 30 kg/m² or higher.
- Scheduled to undergo a colonoscopy under general anesthesia with spontaneous breathing at Bichat-Claude Bernard Hospital, Beaujon Hospital, or Louis Mourier Hospital.
- Affiliated with a social security scheme.
- Free, informed and written consent signed.
Exclusion Criteria:
-
Colonoscopy in a participant at high risk of aspiration requiring orotracheal intubation, defined by at least one of the following:
- Symptomatic or severe gastroesophageal reflux disease, notably with frequent regurgitation (≥ 2 episodes per week), mainly occurring in the supine position;
- Hiatal hernia;
- History of bariatric surgery (sleeve gastrectomy, gastric bypass);
- Neurodegenerative disease requiring airway protection during colonoscopy.
-
Emergency colonoscopy.
-
Chronic respiratory failure.
-
Severe heart failure.
-
Allergy to propofol.
-
Pregnant or breastfeeding woman.
-
Adult under legal protection (guardianship or curatorship).
-
Beneficiary of State Medical Aid (Aide Médicale de l'État, AME).
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Zapobieganie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Pojedynczy
Liczba ramion
Broń i interwencje
Grupa uczestników / ArmGrupa uczestników / Arm |
Interwencja / LeczenieInterwencja / Leczenie |
|---|---|
|
Aktywny komparator: Conventional oxygen therapy
Participants assigned to the conventional oxygen therapy group will receive 100% oxygen at 6 L/min through an oxygen capnography mask during the 3-minute pre-oxygenation period and throughout the procedure. After pre-oxygenation, propofol will be administered by target-controlled intravenous infusion, with an initial target concentration of 2 µg/mL. The anesthetist may adjust the target concentration to achieve deep sedation according to American Society of Anesthesiologists (ASA) criteria. The colonoscopy will be performed while participants breathe spontaneously. |
100% oxygen delivered at a flow rate of 6 L/min through an oxygen capnography mask, during the 3-minute pre-oxygenation period and throughout the colonoscopy performed under general anesthesia (propofol target-controlled infusion) with spontaneous breathing.
Inne nazwy:
|
|
Eksperymentalny: High-flow oxygen therapy
Participants assigned to the high-flow oxygen therapy group will receive 100% oxygen at 50 L/min through an Optiflow® system (Fisher & Paykel Healthcare) during the 3-minute pre-oxygenation period and throughout the procedure. After pre-oxygenation, propofol will be administered by target-controlled intravenous infusion, with an initial target concentration of 2 µg/mL. The anesthetist may adjust the target concentration to achieve deep sedation according to American Society of Anesthesiologists (ASA) criteria. The colonoscopy will be performed while participants breathe spontaneously. |
100% oxygen delivered at a flow rate of 50 L/min through an Optiflow® high-flow nasal system (Fisher & Paykel Healthcare), during the 3-minute pre-oxygenation period and throughout the colonoscopy performed under general anesthesia (propofol target-controlled infusion) with spontaneous breathing.
Inne nazwy:
|
Co mierzy badanie?
Podstawowe miary wyniku
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Number of participants with at least one episode of oxygen desaturation (SpO2 ≤ 90%) during the procedure
Ramy czasowe: From the start to the end of the procedure (Day 0)
|
Oxygen desaturation is defined as a peripheral oxygen saturation (SpO2) ≤ 90%, regardless of its duration, measured by continuous pulse oximetry during the colonoscopy performed under general anesthesia. |
From the start to the end of the procedure (Day 0)
|
Miary wyników drugorzędnych
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Total number of episodes of oxygen desaturation (SpO₂ ≤ 90%) during the procedure
Ramy czasowe: From the start to the end of the procedure (Day 0)
|
Number of desaturation episodes (SpO2 ≤ 90%) per participant, determined from continuously recorded pulse oximetry data. |
From the start to the end of the procedure (Day 0)
|
|
Cumulative duration of oxygen desaturation episodes (SpO2 ≤ 90%) relative to the total duration of the procedure
Ramy czasowe: From the start to the end of the procedure (Day 0)
|
Total time (in seconds) spent with SpO2 ≤ 90%, divided by the total duration of the procedure, i.e. the fraction of procedure time spent in desaturation (between 0 and 1), determined from continuously recorded pulse oximetry data. |
From the start to the end of the procedure (Day 0)
|
|
Occurrence of an episode of hypotension, defined as systolic blood pressure (SBP) < 100 mmHg, during the procedure
Ramy czasowe: From the start to the end of the procedure (Day 0)
|
Determined from continuously recorded non-invasive blood pressure data. |
From the start to the end of the procedure (Day 0)
|
|
Occurrence of an episode of severe bradycardia, defined as heart rate < 40 beats/minute, during the procedure
Ramy czasowe: From the start to the end of the procedure (Day 0)
|
Determined from continuously recorded heart rate data. |
From the start to the end of the procedure (Day 0)
|
|
Use of orotracheal intubation during the procedure
Ramy czasowe: From the start to the end of the procedure (Day 0)
|
Collected from the medical record and reported in the eCRF. |
From the start to the end of the procedure (Day 0)
|
|
Occurrence of a cardiac arrest during the procedure
Ramy czasowe: From the start to the end of the procedure (Day 0)
|
Cardiorespiratory arrest, collected from the medical record and reported in the eCRF |
From the start to the end of the procedure (Day 0)
|
Współpracownicy i badacze
Sponsor
Sponsor
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Szacowany)
Rozpoczęcie studiów
Zakończenie podstawowe (Szacowany)
Zakończenie podstawowe
Ukończenie studiów (Szacowany)
Ukończenie studiów
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Pierwszy wysłany
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia wysłana aktualizacja
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
Inne numery identyfikacyjne badania
- APHP251722
- 2026-A00471-50 (Inny identyfikator: IDRCB)
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .